Nemyatykh Oksana D, Maistrenko Marina A, Demchenko Dina D, Narkevich Igor A, Okovityi Sergey V, Timchenko Vladimir N
Department of Management and Economics of Pharmacy, Faculty of Pharmacy, Saint-Petersburg State Chemical Pharmaceutical University, Ministry of Health of Russia, Prof. Popova Str., 14 Lit. A, 197376 Saint-Petersburg, Russia.
Department of Management and Economics of Pharmacy, Faculty of Pharmacy, Ryazan State Medical University Named after Academician I.P. Pavlov, Ministry of Health of Russia, Vysokovoltnaya Str., 9, 390026 Ryazan, Russia.
J Clin Med. 2023 Jul 17;12(14):4731. doi: 10.3390/jcm12144731.
The purpose of this review was to conduct a comparative assessment of the concepts of therapy for pediatric patients with COVID-19 in the framework of global clinical practice. A structural analysis of the range of drugs and treatment strategies in the context of etiotropic, pathogenetic, and symptomatic therapy has shown that in the global context and in real clinical practice, the etiotropic-pathogenetic approach based on information about the effectiveness of individual medical technologies prevails today. It has been established that eight international nonproprietary/grouping names are present in international practice as means of etiotropic therapy for pediatric patients with COVID-19, and 18 positions are used for pathogenetic therapy. In terms of frequency of occurrence, the leading positions are occupied by remdesivir and the combination of nirmatrelvir with ritonavir, as well as dexamethasone and tocilizumab. The paper emphasizes the relevance of research in the field of evaluating the effectiveness of individual treatment regimens as well as the analysis of the delayed consequences of pathology suffered in childhood under the conditions of using various approaches to pharmacotherapy.
本综述的目的是在全球临床实践框架内，对儿童新冠肺炎患者的治疗概念进行比较评估。在病因性、致病性和对症治疗背景下，对药物和治疗策略范围进行的结构分析表明，在全球范围内和实际临床实践中，基于个体医疗技术有效性信息的病因性-致病性方法如今占主导地位。已确定在国际实践中，有8个国际非专利/分组名称作为儿童新冠肺炎患者病因性治疗手段，18种药物用于致病性治疗。就出现频率而言，领先地位由瑞德西韦、奈玛特韦与利托那韦的组合，以及地塞米松和托珠单抗占据。本文强调了评估个体治疗方案有效性领域研究的相关性，以及在采用各种药物治疗方法的情况下，分析儿童时期所患疾病的延迟后果的重要性。
